Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Total Liabilities (2016 - 2025)

Historic Total Liabilities for CV Sciences (CVSI) over the last 14 years, with Q3 2025 value amounting to $5.5 million.

  • CV Sciences' Total Liabilities fell 1200.0% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of $6.1 million for FY2024, which is 262.03% down from last year.
  • According to the latest figures from Q3 2025, CV Sciences' Total Liabilities is $5.5 million, which was down 1200.0% from $6.1 million recorded in Q2 2025.
  • CV Sciences' Total Liabilities' 5-year high stood at $18.7 million during Q1 2021, with a 5-year trough of $5.5 million in Q3 2025.
  • For the 5-year period, CV Sciences' Total Liabilities averaged around $9.8 million, with its median value being $6.4 million (2024).
  • As far as peak fluctuations go, CV Sciences' Total Liabilities surged by 1081.17% in 2022, and later crashed by 5684.0% in 2023.
  • Quarter analysis of 5 years shows CV Sciences' Total Liabilities stood at $14.5 million in 2021, then dropped by 6.95% to $13.5 million in 2022, then tumbled by 53.4% to $6.3 million in 2023, then fell by 2.62% to $6.1 million in 2024, then decreased by 11.02% to $5.5 million in 2025.
  • Its Total Liabilities stands at $5.5 million for Q3 2025, versus $6.1 million for Q2 2025 and $5.9 million for Q1 2025.